Pancreatic Cancer-targeting Adenovirus Vector Construction Service
Creative Biolabs has always contributed to the development of life sciences by providing scientists with a variety of high-quality biological tools. In order to promote the advancement of tumor gene therapy technology, we have made unremitting efforts to launch pancreatic cancer-targeted adenoviral vector (AV) construction services. Our adenoviral vector construction platform with strict standards can meet customer's requirements. No matter what difficulties you have encountered in the relevant research work, you can contact us to get your customized service.
Pancreatic Cancer-targeting Gene Therapy
Pancreatic cancer is the third leading cause of cancer death in western countries, and its incidence has remained high in the past few decades. There is still no suitable solution to the poor prognosis. This is mainly due to the metastatic nature of this tumor and the lack of systematic and effective treatment. Previous reports suggest that pancreatic cancer will be the second leading cause of cancer deaths in 2030. In order to change this bad situation, scientists need to develop new treatment methods, of which gene therapy is one of the most promising methods.
There are several notable features of gene therapy for pancreatic cancer. First, it requires efficient gene vectors that can transfer a large number of genes with more controllable expression time. Second, it is necessary to accurately locate the target during treatment, because the pancreas is a kind of organs that are closely associated with surrounding blood vessels and other organs. Strict control of gene delivery during gene therapy is necessary. Finally, due to the high invasiveness and increasing rate of pancreatic cancer, it is necessary to consider how to dispose some growth factors that enhance tumor metastasis in treatment.
Adenovirus Vector for Gene Therapy
Oncolytic adenoviruses that are capable of specifically replicating in cancer cells have shown good results in the treatment of various cancer models. These viruses only need to transduce a small number of cells to initiate oncolysis, initiate the replication and spread to other cancer cells, eventually leading to the disappearance of tumor mass. Adenovirus based on human serotype 5 is one of the most ideal vectors for gene therapy. It can produce and infect a variety of cells at high titers both in vivo and in vitro. At present, in order to allow adenovirus to specifically infect cancer cells without affecting other normal cells, there are two ways to construct. The first is to introduce a mutation into the adenovirus E1A gene, and the mutated gene is functionally complemented by genetic mutations in cancer cells, such as p53 mutations. In the second method, transcription of the adenovirus E1 gene is restricted to cancer cells by a tumor or tissue-specific promoters such as the prostate-specific antigen, survivin, midkine, and telomerase reverse transcriptase promoters. In addition, adenoviral vectors can carry and express various genes for treating cancer, including tumor suppressor genes p53, p16, single-chain antibodies, antisense DNase and the like.
Pancreatic Cancer-targeting Adenovirus Vector
Clinical studies of oncolytic adenoviruses have shown that increasing the targeting of adenoviral vectors is key to improve the efficiency of cancer treatment and ensure patient safety. We generally construct targeted adenoviral vectors by directly incorporating ligands for target cell surface receptors into fibrin. Scientists have demonstrated that a pancreatic cancer-targeting sequence, SYENFSA (SYE), which was selected from the adenovirus library by screening against the AsPC-1 pancreatic cancer cell line, significantly enhanced the gene transduction efficiency of the adenoviral vector in pancreatic cancer cell lines but not in normal cells. Subsequently, the SYE sequence was combined with a survivin promoter-regulated oncolytic adenovirus (AdSur-SYE), in which the native tropism was ablated. AdSur-SYE showed higher infectivity and more effective cytotoxicity than the nontargeting oncolytic virus (AdSur) for human pancreatic ductal adenocarcinoma (PDAC).
Creative Biolabs has accumulated a wealth of experience through the success of one project after another. We have introduced different products and services with a rigorous scientific attitude and promoted the continuous development of gene therapy technology. Adenoviral vector construction services targeting pancreatic cancer are once again overcoming the technical difficulties and improving your experimental efficiency with precise targeting and transfection stability. If you have some questions or difficulties, you can contact us by email or send us an inquiry to find a complete solution.
